Global Stem Cell Reconstructive Market- Industry Analysis and Forecast (2020-2027)-by Sources, Cell Type, Application, End User and Region. – WOLE TV

Global Stem Cell Reconstructive Marketwas valued US$ XX Mn in 2019 and is expected to reach US$ XX Mn by 2027, at a CAGR of 24.5% during a forecast period.

Market Dynamics

The Research Report gives an in-depth account of the drivers and restraints in the stem cell reconstructive market. Stem cell reconstructive surgery includes the treatment of injured or dented part of body. Stem cells are undifferentiated biological cells, which divide to produce more stem cells. Growing reconstructive surgeries led by the rising number of limbs elimination and implants and accidents are boosting the growth in the stem cell reconstructive market. Additionally, rising number of aged population, number of patients suffering from chronic diseases, and unceasing development in the technology, these are factors which promoting the growth of the stem cell reconstructive market. Stem cell reconstructive is a procedure containing the use of a patients own adipose tissue to rise the fat volume in the area of reconstruction and therefore helping 3Dimentional reconstruction in patients who have experienced a trauma or in a post-surgical event such as a mastectomy or lumpectomy, brain surgery, or reconstructive surgery as a result of an accident or injury. Stem cell reconstructive surgeries are also used in plastic or cosmetic surgeries as well. Stem cell and regenerative therapies gives many opportunities for development in the practice of medicine and the possibility of an array of novel treatment options for patients experiencing a variety of symptoms and conditions. Stem cell therapy, also recognised as regenerative medicine, promotes the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives.

The common guarantee of all the undifferentiated embryonic stem cells (ESCs), foetal, amniotic, UCB, and adult stem cell types is their indefinite self-renewal capacity and high multilineage differentiation potential that confer them a primitive and dynamic role throughout the developmental process and the lifespan in adult mammal. However, the high expenditure of stem cell reconstructive surgeries and strict regulatory approvals are restraining the market growth.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Global Stem Cell Reconstructive Market Segment analysis

Based on Cell Type, the embryonic stem cells segment is expected to grow at a CAGR of XX% during the forecast period. Embryonic stem cells (ESCs), derived from the blastocyst stage of early mammalian embryos, are distinguished by their capability to distinguish into any embryonic cell type and by their ability to self-renew. Owing to their plasticity and potentially limitless capacity for self-renewal, embryonic stem cell therapies have been suggested for regenerative medicine and tissue replacement after injury or disease. Additionally, their potential in regenerative medicine, embryonic stem cells provide a possible another source of tissue/organs which serves as a possible solution to the donor shortage dilemma. Researchers have differentiated ESCs into dopamine-producing cells with the hope that these neurons could be used in the treatment of Parkinsons disease. Upsurge occurrence of cardiac and malignant diseases is promoting the segment growth. Rapid developments in this vertical contain protocols for directed differentiation, defined culture systems, demonstration of applications in drug screening, establishment of several disease models, and evaluation of therapeutic potential in treating incurable diseases.

Global Stem Cell Reconstructive Market Regional analysis

The North American region has dominated the market with US$ XX Mn. America accounts for the largest and fastest-growing market of stem cell reconstructive because of the huge patient population and well-built healthcare sector. Americas stem cell reconstructive market is segmented into two major regions such as North America and South America. More than 80% of the market is shared by North America due to the presence of the US and Canada.

Europe accounts for the second-largest market which is followed by the Asia Pacific. Germany and UK account for the major share in the European market due to government support for research and development, well-developed technology and high healthcare expenditure have fuelled the growth of the market. This growing occurrence of cancer and diabetes in America is the main boosting factor for the growth of this market.

The objective of the report is to present a comprehensive analysis of the Global Stem Cell Reconstructive Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding Global Stem Cell Reconstructive Market dynamics, structure by analysing the market segments and projects the Global Stem Cell Reconstructive Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Stem Cell Reconstructive Market make the report investors guide. Scope of the Global Stem Cell Reconstructive Market

Global Stem Cell Reconstructive Market, By Sources

Allogeneic Autologous o Bone Marrow o Adipose Tissue o Blood Syngeneic Other Global Stem Cell Reconstructive Market, By Cell Type

Embryonic Stem Cell Adult Stem Cell Global Stem Cell Reconstructive Market, By Application

Cancer Diabetes Traumatic Skin Defect Severe Burn Other Global Stem Cell Reconstructive Market, By End-User

Hospitals Research Institute Others Global Stem Cell Reconstructive Market, By Regions

North America Europe Asia-Pacific South America Middle East and Africa (MEA) Key Players operating the Global Stem Cell Reconstructive Market

Osiris Therapeutics NuVasives Cytori Therapeutics Takeda (TiGenix) Cynata Celyad Medi-post Anterogen Molmed Baxter Eleveflow Mesoblast Ltd. Micronit Microfluidics TAKARA BIO INC. Tigenix Capricor Therapeutics Astellas Pharma US, Inc. Pfizer Inc. STEMCELL Technologies Inc.

Global Stem Cell Reconstructive Market Request For View Sample Report Page : @https://www.maximizemarketresearch.com/request-sample/54688

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info: Name: Vikas Godage Organization: MAXIMIZE MARKET RESEARCH PVT. LTD. Email: sales@maximizemarketresearch.com Website:www.maximizemarketresearch.com

View original post here:
Global Stem Cell Reconstructive Market- Industry Analysis and Forecast (2020-2027)-by Sources, Cell Type, Application, End User and Region. - WOLE TV

Stem Cell Reconstructive Market Will Reflect Significant Growth Prospects of US$ Mn during 2020-2025 with Major Key Player: NuVasive, Cytori…

Latest Research Report: Stem Cell Reconstructive industry

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

Global Stem Cell Reconstructive Market documents a detailed study of different aspects of the Global Market. It shows the steady growth in market in spite of the fluctuations and changing market trends. The report is based on certain important parameters.

Stem cell reconstructive surgery involves the treatment of injured or damaged part of body. Stem cells are undifferentiated biological cells, which divide to produce more stem cells.

Get a Sample PDF copy of the report @ https://reportsinsights.com/sample/13836

Stem Cell Reconstructive Market competition by top manufacturers as follow: , Osiris Therapeutics, NuVasive, Cytori Therapeutics, Takeda (TiGenix), Cynata, Celyad, Medi-post, Anterogen, Molmed

The risingtechnology in Stem Cell Reconstructivemarketis also depicted in thisresearchreport. Factors that are boosting the growth of the market, and giving a positive push to thrive in the global market is explained in detail. It includes a meticulous analysis of market trends, market shares and revenue growth patterns and the volume and value of the market. It is also based on a meticulously structured methodology. These methods help to analyze markets on the basis of thorough research and analysis.

The Type Coverage in the Market are: Embryonic Stem Cell Adult Stem Cell

Market Segment by Applications, covers: Hospitals Research Institutes Others

The research report summarizes companies from different industries. This Stem Cell Reconstructive Market report has been combined with a variety of market segments such as applications, end users and sales. Focus on existing market analysis and future innovation to provide better insight into your business. This study includes sophisticated technology for the market and diverse perspectives of various industry professionals.

Stem Cell Reconstructive is the arena of accounting worried with the summary, analysis and reporting of financial dealings pertaining to a business. This includes the training of financial statements available for public ingesting. The service involves brief, studying, checking and reporting of the financial contacts to tax collection activities and objects. It also involves checking and making financial declarations, scheming accounting systems, emerging finances and accounting advisory.

To get this report at a profitable rate.: https://reportsinsights.com/discount/13836

Market segment by Regions/Countries, this report covers North America Europe China Rest of Asia Pacific Central & South America Middle East & Africa

Report Highlights: Detailed overview of parent market Changing market dynamics in the industry In-depth market segmentation Historical, current and projected market size in terms of volume and value Recent industry trends and developments Competitive landscape Strategies of key players and products offered Potential and niche segments, geographical regions exhibiting promising growth A neutral perspective on market performance Must-have information for market players to sustain and enhance their market footprint

Access full Report Description, TOC, Table of Figure, Chart, [emailprotected] https://reportsinsights.com/industry-forecast/Stem-Cell-Reconstructive-Market-13836

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

Contact US:

:(US) +1-214-272-0234

:(APAC) +91-7972263819

Email:[emailprotected]

Sales:[emailprotected]

Read more here:
Stem Cell Reconstructive Market Will Reflect Significant Growth Prospects of US$ Mn during 2020-2025 with Major Key Player: NuVasive, Cytori...

Global Stem Cell Reconstructive Market- Industry Analysis and Forecast (2020-2027)-by Sources, Cell Type, Application, End User and Region. – Red…

Global Stem Cell Reconstructive Market was valued US$ XX Mn in 2019 and is expected to reach US$ XX Mn by 2027, at a CAGR of 24.5% during a forecast period.

Market Dynamics

The Research Report gives an in-depth account of the drivers and restraints in the stem cell reconstructive market. Stem cell reconstructive surgery includes the treatment of injured or dented part of body. Stem cells are undifferentiated biological cells, which divide to produce more stem cells. Growing reconstructive surgeries led by the rising number of limbs elimination and implants and accidents are boosting the growth in the stem cell reconstructive market. Additionally, rising number of aged population, number of patients suffering from chronic diseases, and unceasing development in the technology, these are factors which promoting the growth of the stem cell reconstructive market. Stem cell reconstructive is a procedure containing the use of a patients own adipose tissue to rise the fat volume in the area of reconstruction and therefore helping 3Dimentional reconstruction in patients who have experienced a trauma or in a post-surgical event such as a mastectomy or lumpectomy, brain surgery, or reconstructive surgery as a result of an accident or injury. Stem cell reconstructive surgeries are also used in plastic or cosmetic surgeries as well. Stem cell and regenerative therapies gives many opportunities for development in the practice of medicine and the possibility of an array of novel treatment options for patients experiencing a variety of symptoms and conditions. Stem cell therapy, also recognised as regenerative medicine, promotes the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives.

The common guarantee of all the undifferentiated embryonic stem cells (ESCs), foetal, amniotic, UCB, and adult stem cell types is their indefinite self-renewal capacity and high multilineage differentiation potential that confer them a primitive and dynamic role throughout the developmental process and the lifespan in adult mammal. However, the high expenditure of stem cell reconstructive surgeries and strict regulatory approvals are restraining the market growth.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Global Stem Cell Reconstructive Market Segment analysis

Based on Cell Type, the embryonic stem cells segment is expected to grow at a CAGR of XX% during the forecast period. Embryonic stem cells (ESCs), derived from the blastocyst stage of early mammalian embryos, are distinguished by their capability to distinguish into any embryonic cell type and by their ability to self-renew. Owing to their plasticity and potentially limitless capacity for self-renewal, embryonic stem cell therapies have been suggested for regenerative medicine and tissue replacement after injury or disease. Additionally, their potential in regenerative medicine, embryonic stem cells provide a possible another source of tissue/organs which serves as a possible solution to the donor shortage dilemma. Researchers have differentiated ESCs into dopamine-producing cells with the hope that these neurons could be used in the treatment of Parkinsons disease. Upsurge occurrence of cardiac and malignant diseases is promoting the segment growth. Rapid developments in this vertical contain protocols for directed differentiation, defined culture systems, demonstration of applications in drug screening, establishment of several disease models, and evaluation of therapeutic potential in treating incurable diseases.

Global Stem Cell Reconstructive Market Regional analysis

The North American region has dominated the market with US$ XX Mn. America accounts for the largest and fastest-growing market of stem cell reconstructive because of the huge patient population and well-built healthcare sector. Americas stem cell reconstructive market is segmented into two major regions such as North America and South America. More than 80% of the market is shared by North America due to the presence of the US and Canada.

Europe accounts for the second-largest market which is followed by the Asia Pacific. Germany and UK account for the major share in the European market due to government support for research and development, well-developed technology and high healthcare expenditure have fuelled the growth of the market. This growing occurrence of cancer and diabetes in America is the main boosting factor for the growth of this market.

The objective of the report is to present a comprehensive analysis of the Global Stem Cell Reconstructive Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding Global Stem Cell Reconstructive Market dynamics, structure by analysing the market segments and projects the Global Stem Cell Reconstructive Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Stem Cell Reconstructive Market make the report investors guide. Scope of the Global Stem Cell Reconstructive Market

Global Stem Cell Reconstructive Market, By Sources

Allogeneic Autologous o Bone Marrow o Adipose Tissue o Blood Syngeneic Other Global Stem Cell Reconstructive Market, By Cell Type

Embryonic Stem Cell Adult Stem Cell Global Stem Cell Reconstructive Market, By Application

Cancer Diabetes Traumatic Skin Defect Severe Burn Other Global Stem Cell Reconstructive Market, By End-User

Hospitals Research Institute Others Global Stem Cell Reconstructive Market, By Regions

North America Europe Asia-Pacific South America Middle East and Africa (MEA) Key Players operating the Global Stem Cell Reconstructive Market

Osiris Therapeutics NuVasives Cytori Therapeutics Takeda (TiGenix) Cynata Celyad Medi-post Anterogen Molmed Baxter Eleveflow Mesoblast Ltd. Micronit Microfluidics TAKARA BIO INC. Tigenix Capricor Therapeutics Astellas Pharma US, Inc. Pfizer Inc. STEMCELL Technologies Inc.

Global Stem Cell Reconstructive Market Request For View Sample Report Page : @ https://www.maximizemarketresearch.com/request-sample/54688

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info: Name: Vikas Godage Organization: MAXIMIZE MARKET RESEARCH PVT. LTD. Email: sales@maximizemarketresearch.com Website:www.maximizemarketresearch.com

View post:
Global Stem Cell Reconstructive Market- Industry Analysis and Forecast (2020-2027)-by Sources, Cell Type, Application, End User and Region. - Red...

Orthopedic Regenerative Medicine Market Insights and Business Outlook By Top Players Curasan, Inc., Carmell Therapeutics Corporation, Anika…

A new business intelligence report released by CMI with title GlobalOrthopedic Regenerative Medicine MarketResearch Report 2019-2027 is designed covering micro level of analysis by manufacturers and key business segments. The Global Orthopedic Regenerative Medicine Market survey analysis offers energetic visions to conclude and study market size, market hopes, and competitive surroundings. The research is derived through primary and secondary statistics sources and it comprises both qualitative and quantitative detailing. Some of the key players profiled in the study are Curasan, Inc., Carmell Therapeutics Corporation, Anika Therapeutics, Inc., Conatus Pharmaceuticals Inc., Histogen Inc., Royal Biologics, Ortho Regenerative Technologies, Inc., Swiss Biomed Orthopaedics AG, Osiris Therapeutics, Inc., and Octane Medical Inc.

Whats keeping Curasan, Inc., Carmell Therapeutics Corporation, Anika Therapeutics, Inc., Conatus Pharmaceuticals Inc., Histogen Inc., Royal Biologics, Ortho Regenerative Technologies, Inc., Swiss Biomed Orthopaedics AG, Osiris Therapeutics, Inc., and Octane Medical Inc. Ahead in the Market? Benchmark yourself with the strategic moves and findings recently released by CMI

Leading players of Orthopedic Regenerative Medicine Market:

Curasan, Inc., Carmell Therapeutics Corporation, Anika Therapeutics, Inc., Conatus Pharmaceuticals Inc., Histogen Inc., Royal Biologics, Ortho Regenerative Technologies, Inc., Swiss Biomed Orthopaedics AG, Osiris Therapeutics, Inc., and Octane Medical Inc.

Orthopedic Regenerative Medicine Geographical Segmentation Includes:

North America (U.S., Canada, Mexico)

Europe (U.K., France, Germany, Spain, Italy, Central & Eastern Europe, CIS)

Asia Pacific (China, Japan, South Korea, ASEAN, India, Rest of Asia Pacific)

Latin America (Brazil, Rest of L.A.)

Middle East and Africa (Turkey, GCC)

The research report includes an exploration of the competitive landscape present in the Orthopedic Regenerative Medicine Market. It includes an import of the current and future trends that players can invest in. Likewise, it also includes an estimation of the business outlooks of the players and explains the nature of the competition.

Orthopedic Regenerative Medicine Market Segmentation

By Procedure Cell TherapyTissue EngineeringBy Cell TypeInduced Pluripotent Stem Cells (iPSCs)Adult Stem CellsTissue Specific Progenitor Stem Cells (TSPSCs),Mesenchymal Stem Cells (MSCs)Umbilical Cord Stem Cells (UCSCs)Bone Marrow Stem Cells (BMSCs)By SourceBone MarrowUmbilical Cord BloodAdipose TissueAllograftsAmniotic FluidBy ApplicationsTendons RepairCartilage RepairBone RepairLigament RepairSpine RepairOthers

The plus point of this research study is that it includes the impact of COVID-19 to the Orthopedic Regenerative Medicine market. The data summarized within this research study includes forecast from 2020 to 2027. COVID-19 has significantly impacted each and every market on the global platform. If you have any specific requirement then Please get in touch with us. Our Expert team will provide as per report customized to your requirement.

Important Features of the report:

Reasons for buying this report:

It offers the regional analysis of the Orthopedic Regenerative Medicine Market along with the business profiles of several stakeholders.

Some Major TOC Points:

Chapter 1. Orthopedic Regenerative Medicine Market Report Overview

Chapter 2. Orthopedic Regenerative Medicine industry Growing Trends

Chapter 3. Market Share by Key vendors

Chapter 4. Orthopedic Regenerative Medicine Market Breakdown Data by Type and Application

Chapter 5. Orthopedic Regenerative Medicine Market by End Users/Application

Chapter 6. COVID-19 Outbreak: Orthopedic Regenerative Medicine Industry Impact

Chapter 7. Opportunity Analysis in Covid-19 Crisis

Chapter 9. Market Driving Factors

And Many More

Apply Promo Code CMIFIRST1000 And Get Instant Discount OfUSD 1000

Download PDF Brochure Of this Report @https://www.coherentmarketinsights.com/insight/request-pdf/3566

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, LATAM, West Europe, MENA Countries, Southeast Asia or Asia Pacific.

About us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contacts US

Mr. Shah US +1-206-701-6702/UK +44-020 8133 4027 Email: [emailprotected]arketinsights.com

More here:
Orthopedic Regenerative Medicine Market Insights and Business Outlook By Top Players Curasan, Inc., Carmell Therapeutics Corporation, Anika...

Books: Five new books to read this week – HeraldScotland

All The Lonely People by Mike Gayle is published in hardback by Hodder & Stoughton, priced 14.99 (ebook 4.99)

Hubert Bird is old and lonely. In weekly phone calls to his daughter Rose, who lives in Australia, he paints the picture of a perfect busy retirement, filled with friends and outings, when the reality is anything but. When Rose announces she is coming to stay, he realises he needs to make some changes. A young mother moves into the neighbourhood and the pair strike up an unlikely friendship as they start a campaign to tackle loneliness in the area. This timely and poignant book flits between present day and Hubert's early life, emigrating to the UK as one of the Windrush generation. Mike Gayle's writing is beautiful and engaging and All The Lonely People is both heartbreaking and uplifting, devastating and thought-provoking. It is the kind of book you will want to press into the hands of everyone you know and tell them to read immediately.

All Adults Here by Emma Straub is published in hardback by Michael Joseph, priced 14.99 (ebook 9.49)

The challenging journey through adulthood is explored with perceptive wit in Emma Straub's entertaining new novel. All Adults Here charts the complicated relationships of the Strick family in the fictional small US town of Clapham. At its heart is family matriarch Astrid, who witnesses a shocking tragedy that sparks a re-examination of her life. As she opens up to her adult children - frustrated Elliott, single-mum-to-be Porter and bohemian Nicky - it turns out they also have secrets and hang-ups to spill. Straub endearingly portrays her central characters as they tangle with a multi-generational crew of friends and relatives. Her easy writing style combines wry humour with the occasional poignant insight. At times the comic tone feels jarring when the novel addresses more serious themes, skipping too lightly over a character's inner complexities. But this is a book that whips along with feel-good momentum, driven by warmth and love.

Pondweed by Lisa Blower is published in hardback by Myriad Editions, priced 12.99 (ebook 5.58)

Lisa Blower is a highly-regarded short-story writer, and her new novel tells the story of an unlikely road trip undertaken by two endearing and idiosyncratic people. Pondweed centres on a couple of late 60-somethings, Selwyn and Ginny. Next-door neighbours in their youth, they once courted and have now got together again - after a fashion-following a 50-year interval. They think they know each others' distant pasts intimately - but are not so strong on anything since. In the interim, Ginny had a daughter and not much else happened for her; Selwyn developed his passion for ponds. But cheated by his business partner out of his pension, Selwyn decides to take the pair of them off on a trip down memory lane in the direction of Wales, armed only with a stolen caravan full of booze and ornamental fish. The road trip quickly turns out to be a painful, poignant and charming journey through the couple's past, as a series of apparently impromptu stop-offs start to trigger forgotten memories, unresolved conflicts, and only partially buried secrets. An unlikely romance between two people who are meant for each other, but don't know how to be together, Pondweed is a delightful read.

Sex Robots & Vegan Meat by Jenny Kleeman is published in hardback by Picador, priced 12.99 (ebook 8.99)

Synthetic wombs, do-it-yourself euthanasia, AI sex robots and meat grown from stem cells: are these the plots of dystopian horror movies or the technologies that will save the future of humankind? Documentary film-maker and journalist Jenny Kleeman explores birth, death, sex and food, navigating opinions, facts and half-truths. In doing so, she must negotiate with an array of distinctive characters (including evangelistic vegans, competitive scientists, and even incels), all of whom vie for centre stage. The real treat is Kleeman's insatiable curiosity, pushing her to ask the difficult questions, even when conversations take an awkward turn (as they so often do). Coupled with her own knee-jerk emotions, assumptions and personal views, her narration ends up being part fact-finding mission, part-storytelling. Whether she's right or wrong isn't really the point; it's whether you agree, disagree, or are downright horrified by the promises of this whole new world. A moreish page-turner of a book that will leave you feeling informed and ready for the next dinner party.

Children's book of the week

The Secret Explorers and the Comet Collision is published in hardback by DK, priced 15.31 (ebook 2.99)

Space and the universe are the setting for the first instalment of DK's new educational series for children, which introduces us to the Secret Explorers, a team of elite mini adventurers. Each of the eight explorers has a unique expertise and has been brought together from around the world to solve special secret missions. In Comet Collision - one of two initial books in the series - space whiz Roshni and rain forest expert Ollie are picked to blast off for a mission to Jupiter to fix a broken space probe. We see Roshni go on a daring spacewalk as the duo work against the clock to complete their mission before a comet strikes. From facts about Jupiter's rings and space probes to asteroids and gravity, the story is perfect for little stargazers aged seven and above, though it can be a little clunky at times during the educational bits.

See the original post:
Books: Five new books to read this week - HeraldScotland

Orthopedic Regenerative Medicine Market Research Report 2020 Overall Analysis and Forecast up to the Year 2027 – Sanford Philosopher

Orthopedic Regenerative Medicine Market Report is an objective and comprehensive study of the current state expected at the major drivers, market strategies, and key vendors growth. The study also includes the important achievements of the market, Research & development and regional growth of the leading competitors operating in the market.

This report also explain the numerous factors that form a significant element of the market. It includes the definition and the scope of the market with a detailed explanation of the market drivers, opportunities, restraints, and threats.

Get Sample Report (including full TOC, Tables and Figures): https://www.coherentmarketinsights.com/insight/request-sample/3566

Leading players of Orthopedic Regenerative Medicine Market:

Curasan, Inc., Carmell Therapeutics Corporation, Anika Therapeutics, Inc., Conatus Pharmaceuticals Inc., Histogen Inc., Royal Biologics, Ortho Regenerative Technologies, Inc., Swiss Biomed Orthopaedics AG, Osiris Therapeutics, Inc., and Octane Medical Inc.

Orthopedic Regenerative Medicine Geographical Segmentation Includes:

North America (U.S., Canada, Mexico)

Europe (U.K., France, Germany, Spain, Italy, Central & Eastern Europe, CIS)

Asia Pacific (China, Japan, South Korea, ASEAN, India, Rest of Asia Pacific)

Latin America (Brazil, Rest of L.A.)

Middle East and Africa (Turkey, GCC)

The research report includes an exploration of the competitive landscape present in the Orthopedic Regenerative Medicine Market. It includes an import of the current and future trends that players can invest in. Likewise, it also includes an estimation of the business outlooks of the players and explains the nature of the competition.

Orthopedic Regenerative Medicine Market Segmentation

By Procedure Cell TherapyTissue EngineeringBy Cell TypeInduced Pluripotent Stem Cells (iPSCs)Adult Stem CellsTissue Specific Progenitor Stem Cells (TSPSCs),Mesenchymal Stem Cells (MSCs)Umbilical Cord Stem Cells (UCSCs)Bone Marrow Stem Cells (BMSCs)By SourceBone MarrowUmbilical Cord BloodAdipose TissueAllograftsAmniotic FluidBy ApplicationsTendons RepairCartilage RepairBone RepairLigament RepairSpine RepairOthers

The plus point of this research study is that it includes the impact of COVID-19 to the Orthopedic Regenerative Medicine market. The data summarized within this research study includes forecast from 2020 to 2027. COVID-19 has significantly impacted each and every market on the global platform. If you have any specific requirement then Please get in touch with us. Our Expert team will provide as per report customized to your requirement.

[**NOTE: Enquiry before Buying option enables you to share your queries, in advance to procure the report. Kindly fill the enquiry form, and one of our consultants would get in touch with you to discuss the queries and would address them.]

Else place an Inquire before Purchase GlobalOrthopedic Regenerative Medicine Market Size, Share, Growth, and Forecast 2027 @https://www.coherentmarketinsights.com/insight/request-customization/3566

Important Features of the report:

Reasons for buying this report:

It offers the regional analysis of the Orthopedic Regenerative Medicine Market along with the business profiles of several stakeholders.

Some Major TOC Points:

Chapter 1. Orthopedic Regenerative Medicine Market Report Overview

Chapter 2. Orthopedic Regenerative Medicine industry Growing Trends

Chapter 3. Market Share by Key vendors

Chapter 4. Orthopedic Regenerative Medicine Market Breakdown Data by Type and Application

Chapter 5. Orthopedic Regenerative Medicine Market by End Users/Application

Chapter 6. COVID-19 Outbreak: Orthopedic Regenerative Medicine Industry Impact

Chapter 7. Opportunity Analysis in Covid-19 Crisis

Chapter 9. Market Driving Factors

And Many More

Buy this Complete Business Report @ https://www.coherentmarketinsights.com/insight/buy-now/3566

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, LATAM, West Europe, MENA Countries, Southeast Asia or Asia Pacific.

Contacts US

Mr. Shah Email:[emailprotected] Phone: US +1-206-701-6702/UK +44-020 8133 4027

See original here:
Orthopedic Regenerative Medicine Market Research Report 2020 Overall Analysis and Forecast up to the Year 2027 - Sanford Philosopher

BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Corporate and R&D Update – Yahoo Finance

NEW YORK, July 27, 2020 /PRNewswire/ --BrainStorm-Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that the Company will hold a conference call to update shareholders on financial results for the second quarter ended June 30, 2020, and provide a corporate update, at 8:00 a.m., Eastern Daylight Time (EDT), on Wednesday, August 5 2020.

On the call, BrainStorm CEO Chaim Lebovits will present a corporate update, including details on the timeline for the data readout of the Company's Phase 3 pivotal trial studying the safety and efficacy of NurOwn (MSC-NTF cell) in people with ALS. In addition, Dr. Revital Aricha. Brainstorm's Vice President of Research and Development, will provide an R&D update including recently announced data from the Company's groundbreaking preclinical study evaluating NurOwn-derived exosomes for the treatment of COVID-19 ARDS.

Thereafter, senior management officers will join the call for a Q&A session. Participants are encouraged to submit their questions prior to the call by sending them to:q@brainstorm-cell.com. Questions should be submitted by5:00 p.m. EDT,Monday, August 3, 2020.

Teleconference Details BRAINSTORM CELL THERAPEUTICS 2Q 2020

The investment community may participate in the conference call by dialing the following numbers:

Participant Numbers:

Toll Free: 877-407-9205 International: 201-689-8054

Those interested in listening to the conference call live via the internet may do so by visiting the "Investors & Media" page of BrainStorm's website atwww.ir.brainstorm-cell.comand clicking on the conference call link.

Those that wish to listen to the replay of the conference call can do so by dialing the numbers below. The replay will be available for 14 days.

Replay Number:

Toll Free: 877-481-4010 International: 919-882-2331 Replay Passcode: 36017

Teleconference Replay Expiration:

Wednesday, August 19, 2020

About NurOwn

NurOwn (autologous MSC-NTF) cells represent a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm also recently received acceptance from theU.S. Food and Drug Administration(FDA) to initiate a Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS) and initiated enrollment inMarch 2019.

AboutBrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc.is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from theU.S. Food and Drug Administration(FDA) and theEuropean Medicines Agency(EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at sixU.S.sites supported by a grant from theCalifornia Institute for Regenerative Medicine(CIRM CLIN2-0989). The pivotal study is intended to support a filing forU.S.FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently receivedU.S.FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS). The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) started enrollment inMarch 2019. For more information, visit the company's website atwww.brainstorm-cell.com.

Story continues

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStorm Cell Therapeutics Inc.'sactual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm's need to raise additional capital, BrainStorm's ability to continue as a going concern, regulatory approval of BrainStorm's NurOwn treatment candidate, the success of BrainStorm's product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm's NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm's ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm's ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Investor Relations:Preetam Shah, MBA, PhD Chief Financial Officer BrainStorm Cell Therapeutics Inc. Phone: +1-862-397-1860 pshah@brainstorm-cell.com

Media:Paul Tyahla SmithSolve Phone: +1-973-713-3768 Paul.tyahla@smithsolve.com

View original content:http://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-to-announce-second-quarter-financial-results-and-provide-a-corporate-and-rd-update-301100141.html

SOURCE Brainstorm Cell Therapeutics Inc

Go here to read the rest:
BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Corporate and R&D Update - Yahoo Finance

New Study Offers First Glimpse Into How Widespread COVID-19 Antibodies are in Canada’s Adult Population – Canada NewsWire

Initial results indicate fewer than 1 in 100 blood donations have antibodies to the novel coronavirus that causes COVID-19.

MONTREAL, OTTAWA, ON, and TORONTO, July 23, 2020 /CNW Telbec/ -Today, Canadian Blood Services and Canada's COVID-19 Immunity Task Force (CITF) are releasing initial results of the first 10,000 blood donor samples assessed for SARS-CoV-2 antibodies. This analysis reveals that over the period from May 9 through June 8, 2020, fewer than 1 per cent of the 10,000 samples from blood donors tested positive for antibodies to the novel coronavirus. Antibodies indicate past infection with SARS-CoV-2, and population studies like this one tell us how many people have likely been exposed to the virus.

These results offer a first, high-level glimpse into an ongoing Canadian Blood Services study assessing SARS-CoV-2 antibodies across nine provinces. They will be updated once Canadian Blood Services completes their analysis of the full sample of 37,800 donations made during the months of May and June 2020. In addition, Hma-Qubec will have results for Quebec in the near future, which will be important for a complete national picture, given the COVID-19 rates in that province.

While there will be adjustments to this initial figure once the full 10-province study is completed in the coming weeks, Professor Catherine Hankins, CITF Co-Chair, believes its implications bear public attention immediately, as reopening is causing a worrisome uptick in COVID-19 cases across Canada.

"What is clear is that only a small percentage of adult Canadians has been infected by SARS-CoV-2," Hankins says. "By far, the majority of us remain vulnerable to infection. We need to ramp up testing and tracing capacity across the country to interrupt any chains of transmission quickly to prevent unchecked spread."

CITF Co-Chair Professor David Naylor concurred: "These data suggest there are several undetected infections for every case confirmed with swabs and RNA tests. That lends weight to current public health advice. Please wear a mask in public indoor spaces, wash your hands often, and practice physical distancing if you're around people who aren't in your COVID-19 'bubble'."

Acknowledging that many more adult Canadians are infected than currently documented, Professor Timothy Evans, CITF Executive Director cautioned against over-interpreting the apparent reduction in risk. "Among adults, the death rate from being infected with SARS-CoV-2 is likely closer to one per cent, as compared to the eight per cent reported to date among those diagnosed with COVID-19. But this is a highly infective virus that could take a huge toll if we allow it to spread, and we are only now learning that many survivors have persistent symptoms."

These initial results from Canadian Blood Services and CITF are a first step toward giving policymakers a deeper understanding of the COVID-19 infection rate across Canada. As further samples are analyzed by Canadian Blood Services and Hma-Qubec, the findings will offer new insights to help guide effective public health measures.

"I want to thank Canadians for the sacrifices made to flatten the curve in the first wave. While these first results reflect widespread adherence with public health measures, they also mean most Canadians remain susceptible to infection,"says the Honourable Patty Hajdu, Minister of Health."As we start to see case numbers rise again, we all need to follow public health advice and avoid crowded places, close-contact settings and confined spaces."

When the Government of Canada established CITF in late April 2020, Canadian Blood Services and Hma-Qubec reached out to offer their assistance. Canada's blood system became the first place the initiative looked for evidence of infection and immunity in the Canadian population.

The choice was obvious. Blood donation centres are a rapid and reliable resource for generating insights into the patterns of illness, such as COVID-19, in the broader population. Canadian Blood Services and Hma-Qubec routinely test blood donations, including tests for pathogens that can be transmitted through transfusion (SARS-CoV2 is not known to be transfusion-transmitted). Both organizations also regularly contribute to active, ethics-approved research programs like this one, some of which in the past have included seroprevalence work to guide policies.

"Canadian Blood Services is proud to support the CITF's mandate," says Dr. Graham Sher, Chief Executive Officer, Canadian Blood Services. "We are uniquely positioned to help by providing information on the presence of COVID-19 antibodies in a large number of people across Canada relatively quickly. This is a great opportunity and privilege for blood donors and staff at Canadian Blood Services to contribute to a national need in a novel way."

"Getting an early picture of the levels of population immunity is critical to inform the public health response," says Dr. Marc Germain, Vice-President, Medical Affairs and Innovation, Hma-Qubec. "We look forward in the coming days to sharing the results of the first study on antibodies to SARS-CoV-2 among blood donors in Quebec."

About the COVID-19 Immunity Task Force

The Government of Canada launched the COVID-19 Immunity Task Force in late April 2020 to measure the scope of coronavirus infection in Canada and rapidly provide information to manage the COVID-19 pandemic and safely get Canadians back to work. The Task Force has the mission of ensuring that at least one million Canadian blood samples are collected and tested over the next two years to track the spread of the virus in the general population and shed light on immune responses to it in a diversity of communities, settings, age brackets, and occupational groups across the nation. For more information visit: http://www.covid19immunitytaskforce.ca

About Canadian Blood Services

Canadian Blood Services is a not-for-profit charitable organization. Regulated by Health Canada as a biologics manufacturer and primarily funded by the provincial and territorial ministries of health, Canadian Blood Services operates with a national scope, infrastructure and governance that make it unique within Canadian healthcare. In the domain of blood, plasma, and stem cells, we provide services for patients on behalf of all provincial and territorial governments, except Quebec. The national transplant registry for interprovincial organ sharing and related programs reaches into all provinces and territories, as a biological lifeline for Canadians. For more information visit: blood.ca

SOURCE McGill University

For further information: Media contacts: COVID-19 Immunity Task Force, Katherine Gombay, [emailprotected] / [emailprotected], 514-717-2289; Canadian Blood Services, [emailprotected], 1-877-709-7773

http://www.mcgill.ca

Read the rest here:
New Study Offers First Glimpse Into How Widespread COVID-19 Antibodies are in Canada's Adult Population - Canada NewsWire

US regulations for regenerative medicine advanced therapies – Regulatory Focus

This article examines US regulations and guidance documents for regenerative medicine advanced therapies (RMATs). The author describes the field of regenerative medicine, noting that it is expanding at an accelerated pace, and outlines some of the common terms associated with it. He also addresses the application process for these therapies, accelerated regulatory pathways, market access, and the outlook for RMATs. The author cautions that, as exciting as these therapies are, they require a rigorous and carefully planned approach to ensure a seamless progression to regulatory approval and commercial success. Introduction Regenerative medicine is a rapidly expanding field, offering the potential to treat serious and life-threatening conditions by replacing, or regenerating, human cells, tissues, or organs that have been damaged by disease, trauma, or congenital defects.1 With more than 200 investigational new drug (IND) applications anticipated by the US Food and Drug Administration (FDA) in 2020,2 regenerative medicine should yield many new therapies with enormous benefits to patients, especially those with unmet medical needs. Navigating the complex regulatory environment of regenerative medicine requires companies to engage with the FDA early and often throughout the drug development process to identify and overcome potential obstacles to approval. Many of these therapies are developed by scientific institutions and medical research groups with limited inhouse regulatory resources, so it is advisable to seek external regulatory support early in the planning process. Regenerative medicines defined Regenerative medicines, as defined by the FDA, include cell therapies (non- and genetically modified), therapeutic tissue-engineering products, human cell and tissue products, and combination products using these biologic components, which lead to a sustained effect on cells and tissues. In addition, a combination product (biologic device, biologic drug, or biologic device-drug) can be eligible for regenerative medicine advanced therapy (RMAT) designation when the biological product constituent part is a regenerative medicine therapy and provides the greatest contribution to the overall intended therapeutic effects of the combination product (i.e., the primary mode of action of the combination product is conveyed by the biological product constituent part). In January 2020, the FDA released six final guidances on gene therapy manufacturing and clinical development of products and a draft guidance.3 The FDAs policy to advance the development of safe and effective cell and gene therapies can be found here.4 This article explains some of the terminology and covers the key US regulations and guidance documents. Discussions of a select number of these documents will be published in separate articles in Regulatory Focus. Terminology Cellular & gene therapy products5 Cellular therapy products include cellular immunotherapies, cancer vaccines, and other types of autologous and allogeneic cells, including hematopoietic stem cells and adult and embryonic stem cells, for certain therapeutic indications. Human gene therapy seeks to modify or manipulate the expression of a gene or to alter the biological properties of living cells for therapeutic use. The FDAs Center for Biologics Evaluation and Research (CBER) has approved both cellular and gene therapy products.5 Gene therapy6 Gene therapy is a technique that modifies a persons faulty genes treat or cure disease and is most often applied to cancer, genetic diseases and infectious diseases. Gene therapies can work by several mechanisms:

The following figureshows CBERs organisation for pre and postmarket regulation35

Market access and outlook As of May 2019, the FDA had granted 34 products FDA regenerative medicine advanced therapy designations.36 In all, 68 of the 100 designation applications were cell therapy products, 20 of the 34 RMAT granted products have orphan product designation, and 11 of the 34 have fast track designation. While the promise of regenerative medicines to cure disease is driving the field forward at an accelerated pace, developing these therapies require a rigorous and carefully planned approach to ensure a seamless progression to regulatory approval and commercial success. Abbreviations ANDA, abbreviated new drug application; CBER, Center for Biologics Evaluation and Research; FDA, Food and Drug Administration; HCT/P, human cell, tissue, and cellular and tissue-based product; IND, investigational new drug; PDUFA, Prescription Drug User Fee Act; rDNA, ribosomal DNA; RMAT, regenerative medicine advanced therapy. References All references were accessed 23 July 2020.

Read the original here:
US regulations for regenerative medicine advanced therapies - Regulatory Focus

Scientists discovered the real reason behind goosebumps – Tech Explorist

Human bodies do a lot of weird stuff. But goosebumps may be one of our strangest bodily functions.

Goosebumps are humanitys near-universal reaction to the cold. But for some reason, those unmistakable, tiny bumps on the skin also appear when were scared or when were moved by something awe-inspiring.

A new has discovered the reason behind goosebumps. Scientists from Harvard University suggested that the cells that cause goosebumps are also important for regulating the stem cells that regenerate hair.

Underneath the skin, the muscle that contracts to make goosebumps is essential to connect the sympathetic nerves connection with hair follicle stem cells. The sympathetic nerve responds to cold by contracting the muscle and causing goosebumps in the short term, and by driving hair follicle stem cell activation and new hair development over the long term.

The study was conducted on mice, offers a better comprehension of how different cell types interact to link stem cell activity with changes in the outside environment.

Ya-Chieh Hsu, the Alvin and Esta Star Associate Professor of Stem Cell and Regenerative Biology said,We have always been interested in understanding how stem cell behaviors are regulated by external stimuli. The skin is a fascinating system: it has multiple stem cells surrounded by diverse cell types and is located at the interface between our body and the outside world. Therefore, its stem cells could potentially respond to a diverse array of stimuli from the niche, the whole body, or even the outside environment.

In this study, we identify an interesting dual-component niche that not only regulates the stem cells under steady-state but also modulates stem cell behaviors according to temperature changes outside.

In the skin, three types of tissues (epithelium, mesenchyme, and nerve) are organized in a special arrangement. The sympathetic nerve, part of our nervous system that controls body homeostasis and our responses to external stimuli, connects with a tiny smooth muscle in the mesenchyme. This smooth muscle in turn connects to hair follicle stem cells, a type of epithelial stem cell critical for regenerating the hair follicle as well as repairing wounds.

The connection between the thoughtful nerve and the muscle has been notable since they are the cellular basis behind goosebumps: the cold triggers sympathetic neurons to send a nerve signal, and the muscle reacts by contracting and making the hair stand on end.

However, when examining the skin under extremely high resolution using electron microscopy, scientists demonstrated that the sympathetic nerve not only associated with the muscle but also formed a direct connection to the hair follicle stem cells. In fact, the nerve fibers wrapped around the hair follicle stem cells like a ribbon.

Hsu said,We could really see at an ultrastructure level how the nerve and the stem cell interact. Neurons tend to regulate excitable cells, like other neurons or muscles with synapses. But we were surprised to find that they form similar synapse-like structures with an epithelial stem cell, which is not a very typical target for neurons.

Next, the analysts affirmed that the nerve in fact targeted the stem cells. The sympathetic nervous system is normally initiated at a consistently low level to keep up body homeostasis, and the scientists found that this low level of nerve activity kept up the stem cells in a poised state ready for regeneration. Under prolonged cold, the nerve was enacted at a lot higher level and more neurotransmitters were released, making the stem cells actuate rapidly, recover the hair follicle, and grow new hair.

Scientists also investigated what maintained the nerve connections to the hair follicle stem cells. Removing the sympathetic nerve retracted and the nerve connection to the hair follicle stem cells was lost. It shows that the muscle was necessary for structural support to bridge the sympathetic nerve to the hair follicle.

Yulia Shwartz, a postdoctoral fellow in the Hsu lab said,We discovered that the signal comes from the developing hair follicle itself. It secretes a protein that regulates the formation of the smooth muscle, which then attracts the sympathetic nerve. Then in the adult, the interaction turns around, with the nerve and muscle together regulating the hair follicle stem cells to regenerate the new hair follicle. Its closing the whole circle the developing hair follicle is establishing its own niche.

Through this study, scientists also discovered a two-component system that regulates hair follicle stem cells. The nerve is the signaling component that activates the stem cells through neurotransmitters, while the muscle is the structural component that allows the nerve fibers to directly connect with hair follicle stem cells.

Shwartz said,You can regulate hair follicle stem cells in so many different ways, and they are wonderful models to study tissue regeneration. This particular reaction is helpful for coupling tissue regeneration with changes in the outside world, such as temperature. Its a two-layer response: goosebumps are a quick way to provide some sort of relief in the short term. But when the cold lasts, this becomes a nice mechanism for the stem cells to know its maybe time to regenerate new hair coat.

Scientists are further planning to investigate the way the external environment might influence the stem cells in the skin, both under homeostasis and in repair situations such as wound healing.

Hsu said,We live in a constantly changing environment. Since the skin is always in contact with the outside world, it gives us a chance to study what mechanisms stem cells in our body use to integrate tissue production with changing demands, which is essential for organisms to thrive in this dynamic world.

Follow this link:
Scientists discovered the real reason behind goosebumps - Tech Explorist